KFF Health News published a current U.S. medical or healthcare update on October 26, 2026. The story is receiving priority because the agent rated it as a timely, high-impact topic in drugs, treatments and FDA action. This article summarizes the verified source material and separates confirmed facts from issues that still need to be watched.
What happened?
A proposed federal rule could dramatically reduce access to remote patient monitoring programs for people on Medicare. The services aim to keep patients out of the hospital by giving them devices to monitor their health at home, but critics say there isn’t enough oversight.
Key facts from the source
- Remote monitoring can be used for patients who are in physical therapy, recovering from surgery or hospitalization, or living with a chronic condition such as diabetes or heart disease.
- Van Ostrand said many vendors have already made changes inspired by the “very well-reasoned recommendations” from HHS’ Office of Inspector General and were surprised that the proposed Medicare rule didn’t mandate all its suggestions.
- The proposed rule says outside vendors may “have little to no established relationship” with patients and their clinicians, which it says can “fragment care.” It also says the clinicians may not be involved enough to warrant being paid by Medicare.
- Other patients are given devices such as scales, blood glucose monitors, and fitness bands that transmit data that’s monitored by nurses or other staffers, and, increasingly, with the help of artificial intelligence.
- The number of traditional Medicare patients enrolled in such programs grew tenfold from 2019 to 2023, while program spending on them increased from just under $7 million to more than $194 million, according to an April 2025 report from the Peterson Center on Healthcare.
Why this matters in U.S. healthcare
FDA actions involving drugs, biologics, therapies, or safety warnings can influence treatment options, prescribing information, access, monitoring, and manufacturer responsibilities.
Who may be affected?
Patients, prescribers, pharmacists, hospitals, health plans, manufacturers, and specialty practices may be affected depending on the product and indication.
What to watch next
- Read the FDA announcement and product labeling or safety communication.
- Watch for indication, eligibility, safety, supply, or access details.
- Look for payer and clinical-guideline updates after the federal action.
- Do not treat a news summary as prescribing guidance.
Key takeaway
This is a developing medical-news item selected for recency, U.S. relevance, potential impact, source quality, and independent coverage where available. The original source remains the authority for exact clinical, regulatory, safety, coverage, or policy details.
Frequently asked questions
Is this article medical advice?
No. It is a news summary based on cited public sources and is not a substitute for clinical guidance or patient-specific medical advice.
How current is this story?
The agent prioritizes articles published within its configured hot-news window and rejects older stories from automatic publication.
How is a topic selected?
Stories are ranked using freshness, U.S. relevance, potential healthcare impact, source authority, and corroboration across separate sources.
Sources
Primary source: Many Medicare Patients Could Lose Access to Remote Monitoring Devices — KFF Health News.